United Therapeutics (UTHR) just received FDA clearance to start a phase 1 trial of Treprostinil-Iloprost SMI in healthy volunteers, putting a new pulmonary arterial hypertension candidate on investors’ radar.
United Therapeutics has been in focus for more than just this trial news, with the share price at US$598.60 after a 10.47% 1 month share price return and 15.62% 3 month share price return, alongside FDA clearances, new xenograft facilities and a fresh US$2.0b buyback plan. Over a longer horizon, the 34.39% 1 year total shareholder return and 195.90% 5 year total shareholder return point to momentum that recent clinical and capital allocation updates may be helping to sustain.
Scan other late-stage healthcare stories with similar momentum and see how United Therapeutics compares with a curated list of 34 healthcare AI stocks in the current market.
The business behind United Therapeutics looks powerful, and the recent share price jump plus fresh buyback plan only underline that strength. The real puzzle now is whether the current valuation already reflects it.
Most Popular Narrative: 11% Undervalued
At a last close of $598.60 versus a narrative fair value of about $671, United Therapeutics is framed as undervalued by followers of the most popular thesis. That gap is viewed as hinging on pulmonary fibrosis and xenograft execution more than near term headline moves.
Progress in organ replacement technologies, including three FDA authorized xenograft trials, designated pathogen free organ production facilities targeting several thousand organs per year and the approved LungFX device, lays out a path for new product lines that could add incremental revenue streams and operating leverage beyond the existing pulmonary business.
See why 34 investors see United Therapeutics as 11% undervalued.
Result: Fair Value of $670.93 (UNDERVALUED)
Still, United Therapeutics faces meaningful hurdles if Tyvaso uptake in pulmonary fibrosis underwhelms, or if competitors and generics chip away at the existing PAH franchise.
Find out about the key risks to this United Therapeutics narrative.
Next Steps
Whether you feel optimistic or cautious after all this, you can still benefit from scanning the data yourself and pressure testing the bullish angles the market is watching. Start by reviewing the 3 key rewards.
Ready for more investment ideas beyond United Therapeutics?
If you stop with just one opportunity, you risk missing other stocks that better fit your goals, risk limits and time horizon across sectors and styles.
- Target potential mispricings by scanning a curated set of 29 high quality undervalued stocks that combine quality fundamentals with attractive entry points.
- Lock in recurring cashflow potential by reviewing a focused group of 5 dividend fortresses designed for investors who care about income resilience.
- Prioritize resilience first by filtering a 30 resilient stocks with low risk scores that highlights companies with sturdier balance sheets and lower overall risk profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com